Compare BBLG & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBLG | VRAX |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.8M |
| IPO Year | N/A | 2022 |
| Metric | BBLG | VRAX |
|---|---|---|
| Price | $2.11 | $0.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 37.6K | ★ 15.3M |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,986.00 |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.30 | $0.35 |
| 52 Week High | $7.74 | $3.20 |
| Indicator | BBLG | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 64.95 | 46.82 |
| Support Level | $1.47 | $0.39 |
| Resistance Level | $1.99 | $0.87 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 93.02 | 23.13 |
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).